NCT02952248 2026-01-27
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
260 trialsNCT03156114 2026-01-26
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Boehringer Ingelheim
Phase 1 Completed
NCT04544995 2026-01-21
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
Phase 1 Terminated
NCT03843359 2026-01-08
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT05678998 2026-01-06
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
Phase 1 Completed
NCT01695005 2025-12-26
A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02275910 2025-12-16
Phase 1 Study of E7090 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT02860676 2025-12-15
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
University of California, San Diego
Phase 1 Completed
NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT02197234 2025-11-20
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
AstraZeneca
Phase 1 Completed
NCT02157883 2025-11-19
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
AstraZeneca
Phase 1 Completed
NCT05980416 2025-11-14
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
Phase 1 Terminated
NCT03468426 2025-11-10
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT02964013 2025-10-14
KEYVIBE-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03972150 2025-10-06
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02674152 2025-10-01
Dose Finding Study of BI 836880 in Patients With Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT02689505 2025-10-01
Weekly BI 836880 in Patients With Advanced Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT04147234 2025-08-19
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Completed
NCT05708924 2025-08-14
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT03307629 2025-07-29
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Noxopharm Limited
Phase 1 Completed
NCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT04477759 2025-07-15
DEHART
Medical College of Wisconsin
Phase 1 Completed
NCT01317420 2025-07-11
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
Boehringer Ingelheim
Phase 1 Completed
NCT03128047 2025-07-08
HUMC 1612: Optune NovoTTF-200A System
Hackensack Meridian Health
Phase 1 Completed
NCT03884556 2025-07-02
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT03099174 2025-06-24
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02145741 2025-06-19
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT02663297 2025-05-15
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02875223 2025-04-20
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
Phase 1 Terminated
NCT03724890 2025-04-10
Study of Avelumab-M3814 Combinations
EMD Serono
Phase 1 Completed
NCT02834390 2025-03-05
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT01214616 2025-02-07
BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT03948763 2025-01-28
V941-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01121588 2025-01-23
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Pfizer
Phase 1 Terminated
NCT01946789 2025-01-22
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Altor BioScience
Phase 1 Completed
NCT02751528 2025-01-13
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
NantBioScience, Inc.
Phase 1 Terminated
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT04526509 2024-11-26
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Adaptimmune
Phase 1 Terminated
NCT02972034 2024-11-21
MK-8353-013
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT05943990 2024-11-13
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Adaptimmune
Phase 1 Terminated
NCT01359982 2024-11-01
DINAMIC
EpicentRx, Inc.
Phase 1 Completed
NCT02265536 2024-10-28
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04472650 2024-10-26
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
BeiGene
Phase 1 Completed
NCT04138823 2024-10-09
A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
Phase 1 Completed
NCT03328143 2024-10-03
Feasibility of Aromatherapy in an Awake Craniotomy Environment
Wake Forest University Health Sciences
Phase 1 Completed
NCT02099539 2024-09-26
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
Phase 1 Terminated
NCT03447314 2024-09-23
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed